Metastatic melanoma is a complex and deadly disease. Due to its complexity, the
development of novel therapeutic strategies to inhibit metastatic melanoma remains an …

Brain metastasis is the leading cause of death in most cancer patients; thus, anti‐brain
metastasis is a crucial step in cancer treatment. The unique microenvironment and …

Immunotherapies against brain metastases have shown clinical benefits when applied to
asymptomatic patients, but they are largely ineffective in symptomatic cases for unknown …

Complex 3D bioengineered tumour models provide the opportunity to better capture the
heterogeneity of patient tumours. Patient-derived organoids are emerging as a useful tool to …

Immunotherapies are a key therapeutic strategy to fight cancer. Diverse approaches are
used to activate tumor-directed immunity and to overcome tumor immune escape. The …

Brain metastasis (BM) is a common complication in cancer patients with advanced disease
and attributes to treatment failure and final mortality. Currently there are several therapeutic …

In the era of personalized oncology, there have been accelerated efforts to develop clinically
relevant platforms to test drug sensitivities of individual cancers. An ideal assay will serve as …

Background Breast cancer brain metastasis is a rising occurrence, necessitating a better
understanding of the mechanisms involved for effective management. Breast cancer brain …

Brain metastases (BrMs) and gliomas are two typical human brain tumors with high
incidence of mortalities and distinct clinical challenges, yet the understanding of these two …

Purpose Brain metastases represent the most common intracranial tumors in adults and are
associated with a poor prognosis. We used a personalized in vitro drug screening approach …